TET1 mutation

CI-VAR-00005017Explore in graph →CIViC 5172

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TET1 mutation	Immune Checkpoint Inhibitor	Predictive	C	Supports Sensitivity Response	3	submitted	EID12409 In a retrospective study on TCGA data, the presence of non-synonymous mutations in TET1 is enriched in patients responding to immune checkpoint inhibitor treatment (n=519, P = 0.003). In an ICI-treate… (full text at CIViC) PMID 31623662 · Wu et al., 2019 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.